Chlorpromazine versus piperacetazine for schizophrenia

Area of Science:

• Psychiatry and Mental Health
• Pharmacological Treatments for Psychotic Disorders

Background:

• Schizophrenia is a severe mental disorder affecting approximately 1% of the global population.
• Antipsychotic medications are the primary treatment for schizophrenia, with varying side effect profiles.
• Piperacetazine has shown comparable clinical effectiveness to chlorpromazine, a benchmark antipsychotic.

Purpose of the Study:

• To compare the clinical efficacy and side effect profiles of chlorpromazine versus piperacetazine in patients with schizophrenia.
• To provide an evidence base for informed treatment decisions between these two antipsychotics.

Main Methods:

• Systematic review of randomized controlled trials (RCTs) comparing chlorpromazine and piperacetazine.
• Searched multiple databases including CINAHL, CENTRAL, PubMed, and PsycINFO without language or date limitations.
• Extracted and analyzed data independently, calculating risk ratios and mean differences with 95% confidence intervals.

Main Results:

• Five trials from the 1970s involving 343 participants were included; overall methodology and data reporting were poor.
• No significant difference was observed in global state improvement (psychiatrist-rated) or Brief Psychiatric Rating Scale scores.
• Adverse effects and parkinsonism-type movement disorders occurred similarly in both groups; no clear difference in study withdrawal rates.

Conclusions:

• Chlorpromazine and piperacetazine appear to have similar clinical efficacy and side effect profiles based on limited, very low-quality evidence.
• The small sample sizes and poor quality of included trials prevent firm conclusions.
• High-quality research is needed to guide clinical decisions regarding the choice between chlorpromazine and piperacetazine for schizophrenia.